Morphology transitions induced by chemotherapy in carcinomas "in situ" by Ferreira Jr., S. C. et al.
ar
X
iv
:c
on
d-
m
at
/0
21
26
34
v1
  3
0 
D
ec
 2
00
2
Morphology transitions induced by chemotherapy in carcinomas “in situ”
S. C. Ferreira Jr.∗
Departamento de F´ısica, Instituto de Cieˆncias Exatas, Universidade Federal de Minas Gerais,
Caixa Postal 702, 30161-970 Belo Horizonte, Minas Gerais, Brazil
M. L. Martins†
Departamento de F´ısica, Universidade Federal de Vic¸osa, 36571-000, Vic¸osa, Minas Gerais, Brazil
M. J. Vilela‡
Departamento de Biologia Animal, Universidade Federal de Vic¸osa, 36571-000, Vic¸osa, Minas Gerais, Brazil
(Dated: November 15, 2018)
Recently, we have proposed a nutrient-limited model for the avascular growth of tumors including
cell proliferation, motility and death [1], that, qualitatively reproduces commonly observed mor-
phologies for carcinomas in situ. In the present work, we analyze the effects of distinct chemothera-
peutic strategies on the patterns, scaling and growth laws obtained for such nutrient-limited model.
Two kinds of chemotherapeutic strategies were considered, namely, those that kill cancer cells
and those that block cell mitosis but allows the cell to survive for some time. Depending on the
chemotherapeutic schedule used, the tumors are completely eliminated, reach a stationary size or
grow following power laws. The model suggests that the scaling properties of the tumors are not
affected by the mild cytotoxic treatments, although a reduction in growth rates and an increase in
invasiveness are observed. For the strategies based on antimitotic drugs a morphological transition
in which compact tumors become more fractal under aggressive treatments was seen.
PACS numbers: 87.19+e, 87.18.Hf, 87.18.Bb, 87.15.Vv
I. INTRODUCTION
Cancer is the uncontrolled cellular growth in which
neoplastic cells invade adjacent normal tissues and give
rise to secondary tumors (metastasis) on tissues or or-
gans distant from its primary origin [2]. A cancer that
remains confined within a messed surface, without break
of the underlying basement membrane, is referred to as
carcinoma “in situ”. “In situ” carcinoma is characterized
by intense cytological atypia, necrosis, and frequent and
abnormal mitosis, the tumor cells being arranged in vari-
ous distinctive patterns [3]. A malignant tumor is derived
from a single cell that, years before the tumor becomes
clinically detectable, began an inappropriate pathway of
proliferation [4]. Although cancers are extremely diverse
and heterogeneous, a small number of pivotal steps as-
sociated to both deregulated cell proliferation and sup-
pressed cell death are required for the development of
any and all tumors. Indeed, all neoplasms evolve ac-
cordingly to an universal scheme [5, 6]. In the struggle
against cancer, surgical removal, chemotherapy and/or
radiotherapy are the most commonly used treatment for
the complete eradication of the tumor mass. Nowadays,
new approaches, such as immunotoxins [7], gene [8], anti-
angiogenic [9] and virus [10] therapies, are being devel-
oped and have been successfully used in the treatment of
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several kinds of experimental and human tumors.
Mathematical models are always used as a tentative
for describing cancer growth. In particular, numerous
models based on classical reaction-diffusion equations
have been proposed to investigate the growth of tumor
spheroids [11], cancer progress and its interaction with
the immune system [12], and the tumor angiogenesis
[13, 14]. Fractal growth patterns in gliomas (brain tu-
mors) were recently investigated by Sander and Deis-
boeck [15]. Scalerandi et. al., using the local interaction
simulation approach (LISA), formulated models for the
evolution of avascular tumors [16] and tumor cords [17]
under nutrient competition. They also analyzed the ef-
fects of tumor vascularization [18] on cancer growth. Re-
cently, we have studied a diffusion-limited model for the
growth of carcinomas “in situ” in which cell proliferation,
motility and death are locally controlled by growth fac-
tors [19, 20]. This model generates compact, connected
and disconnected morphologies characterized by Gom-
pertzian growth in time and distinct scaling laws for the
tumor interfaces. In order to generate papillary and ram-
ified morphologies found in many epithelial cancers and
trichoblastomas, we were led to analyze the effects of nu-
trient competition in cancer development [1].
In addition to the vast literature dedicated to tu-
mor growth modeling, many research papers addressing
cancer therapies have recently been published. Indeed,
cancer cell kinetics under treatments using antimitotic
agents [21, 22], radiotherapy [23], virus that replicate
selectively in tumor cells [24], anti-angiogenic chemicals
[25], as wells as the effects of tumor drug resistance and
tumor vasculature on chemotherapies [26], were studied
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using mathematical models.
In this paper it is analyzed the effects of distinct
chemotherapeutic strategies in the model for the growth
of avascular tumors proposed by us [1]. Specifically, we
are interested in possible changes in the tumor patterns,
scaling and growth laws reported on the original model
triggered by chemotherapies. The paper is organized as
follows. In section II the nutrient-limited model for can-
cer growth and its main results are reviewed. In section
III, chemotherapeutic treatments that aim to kill can-
cer cells are introduced in the framework of the present
model and their effects discussed. In section IV, a model
for chemotherapy with antimitotic agents is considered.
Finally, we draw some conclusions in section V.
II. THE NUTRIENT-LIMITED MODEL
Our nutrient-limited model combines macroscopic
reaction-diffusion equations, describing the nutrient field
concentration, with microscopic stochastic rules govern-
ing the actions of individual tumor cells. The basic prin-
ciples included in the model are cell proliferation, motil-
ity and death as well as competition for nutrients among
cancer and normal cells. Also, the nutrient concentration
field locally controls cell division, migration and death.
A. The model
1. The tissue
The tissue, represented by a square lattice of size
(L + 1) × (L + 1) and lattice constant ∆, is fed by a
single capillary vessel at x = 0, the top of the lattice.
The capillary is the unique source from which nutrients
diffuse through the tissue towards the individual cells.
Although a tumor mass is composed of different cell sub-
populations [5], the model considers only three types:
normal, cancer and tumor dead cells. Any site, with co-
ordinates ~x = (i∆, j∆), i, j = 0, 1, 2, . . . , L, is occupied
by only one of these cell types. In contrast to the normal
cells, one or more cancer cells can pile up in a given site.
In turn, dead tumor cells are inert. Thus, each lattice site
can be thought of as a group of cells in which the normal,
dead and cancer cell populations assume one of the pos-
sible values σn(~x) = σd(~x) = 0, 1 and σc(~x) = 0, 1, 2, . . .,
respectively. Accordingly the theory of the monoclonal
origin of cancer [4], a single cancer cell at y = L∆/2 and
at a distance X from the capillary is introduced in the
normal tissue. Periodic boundary conditions along the
horizontal axis are used. The row i = 0 represents the
capillary vessel and the sites with i = L + 1 constitute
the external border of the tissue. This geometry is par-
ticularly adequate to describe the growth of carcinomas
(epithelial tumors) “in situ” because the present model
consider that the tumor mass receive nutrients only by
diffusion from the capillary vessel. However, the model
can be extended to others cancers.
2. The nutrients
The nutrients are divided into two classes: essential to
cell proliferation, those necessary to DNA synthesis, and
nonessential to cell division. The essential and nonessen-
tial nutrients are described by the concentration fields
N(~x, t) and M(~x, t), respectively. These nutrient fields
obey the dimensionless diffusion equations (see ref. [1]
for the complete variable transformations)
∂N
∂t
= ∇2N − α2Nσn − λNα
2Nσc (1)
and
∂M
∂t
= ∇2M − α2Mσn − λMα
2Mσc (2)
in which differentiated nutrient consumption rates for
normal and cancer cells by factors λN and λM are as-
sumed. It is important to notice that the model admits
the simplest form for nutrient diffusion, i. e., linear equa-
tions with constant coefficients. Also, λN > λM is used,
reflecting the larger affinity of cancer cells for essential
nutrients.
The boundary conditions satisfied by the normalized
nutrient concentration fields are N(x = 0) = M(x =
0) = 1, representing the continuous and fixed supply of
nutrients provided by the capillary vessel; N(y = 0) =
N(y = L) and M(y = 0) = M(y = L), corresponding
to the periodic boundary conditions along the y-axis; at
last, Neumann boundary conditions, ∂N(x = L)/∂x =
∂M(x = L)/∂x = 0, are imposed to the border of the
tissue.
3. Cell dynamics
In our original model, each tumor cell, randomly se-
lected with equal probability, can carry out one of three
actions: division, migration or death. However, in the
present work we consider just the accommodation that
happens during cell mitosis among the daughter cells.
Consequently, each tumor cell can carry out one of two
actions.
1. Division. Cancer cells divide by mitosis with prob-
ability Pdiv. If the chosen cell is inside the tu-
mor, its daughter will pile up at that site, and
σc(~x)→ σc(~x)+1. Otherwise, if the selected cell is
on the tumor border, its daughter cell will occupy
at random one of their nearest neighbor sites ~x′ con-
taining a normal or a necrotic cell and, therefore,
σc(~x′) = 1 and σn,d(~x′) = 0. The mitotic proba-
bility Pdiv is determined by the concentration per
cancer cell of the essential nutrients N present on
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the microenvironment of the selected cell:
Pdiv(~x) = 1− exp
[
−
(
N(~x)
σc(~x) θdiv
)2]
. (3)
The Gaussian term is included in order to produce a
sigmoid curve saturated to the unity, and the model
parameter θdiv controls the shape of this sigmoid.
2. Death. Cancer cells die with probability Pdel.
Thus, σc(~x) → σc(~x) − 1 and σd(~x) = 1 when σc
vanishes. The cell death probability Pdel is deter-
mined by the concentration per cancer cells of the
nonessential nutrientsM present on the microenvi-
ronment of the selected cell:
Pdel(~x) = exp
[
−
(
M(~x)
σc(~x) θdel
)2]
, (4)
i. e., a Gaussian distribution whose variance de-
pends on the model parameter θdel.
The biological basis for these cell dynamic rules can
be found in reference [1]. However, it is worthwhile to
notice that from the point of view of the so-called kinetic
cellular theory, which provides a general framework for
the statistical description of the population dynamics of
interacting cells [12], the local probabilities Pdiv and Pdel
can be thought as an effective kinetic cellular model.
4. Computer implementation
The growth model simulations were implemented us-
ing the following procedure. At each time step T , Eqs.
(1) and (2) are numerically solved in the stationary
state (∂N/∂t = ∂M/∂t = 0) through relaxation meth-
ods. Provided the nutrient concentration at any lattice
site, NC(T ) cancer cells are sequentially selected at ran-
dom with equal probability. For each one of them, a
tentative action (division or death) is randomly chosen
with equal probability and the time is incremented by
∆T = 1/NC(T ). The selected cell action will be im-
plemented or not according to the correspondent local
probabilities determined by Eqs. (3) or (4). At the end
of this sequence of NC(T ) tentatives, a new time step
begins and the entire procedure (solution of the diffusion
equations and application of the cell dynamics) is iter-
ated. The simulations stop if any tumor cell reaches the
capillary vessel.
B. Main results
The model reproduces commonly observed tumor mor-
phologies including the papillary, compact and ramified
patterns shown in Fig. 2. The nutrient consumption by
normal and cancer cells, controlled by the model parame-
ters α, λN and λM , plays a central role in morphology se-
lection. For small values of these parameters, correspond-
ing to growth conditions in which individual cells demand
small nutrient supplies, the patterns tend to be compact
and circular (Fig. 2a). However, if the mitotic rate of
cancer cells is small due to the large amount of nutrients
demanded for cell division, generating a significant com-
petition for nutrients, these compact patterns progres-
sively assume papillary-like morphologies (Fig. 2b). At
high nutrient consumption rates these papillary patterns
become the rule and, for low cancer cell division, con-
tinuously transform into thin tips, filaments or chords of
cells (Fig. 2c). Also, the model generates patterns with
a inner core of died cells for high nutrient consumption
or cell division rates (Fig. 2d). As observed in “in vivo”
tumors and “in vitro” multicell spheroids [11], these sim-
ulated patterns consist of three distinct regions: a central
necrotic core, an inner rim of quiescent cancer cells and
a narrow outer shell of proliferating cells.
The tumor patterns generated by our nutrient-limited
model were characterized by its gyration radius Rg, total
number of cancer cells NC , and number of sites on tumor
periphery S (including the surface of holes, if any). The
gyration radius Rg is defined as
Rg =
(
1
n
n∑
i=1
r2i
)1/2
(5)
where n is the number of sites occupied by the pat-
tern (cancer or necrotic cells) and ri is the distance of
the occupied site i from the tumor mass center. These
quantities could be related to clinically important cri-
teria such as progress curves, growth rates (volumetric
doubling time) at given radii, proliferative and necrotic
fractions of the tumor.
The progress in time of cancer cell populations for all
the simulated patterns follows Gompertz curves,
NC(T ) = A exp [− exp(−k(T − Tc))] , (6)
representing an initial exponential growth that is satu-
rated in larger times.
Alternatively, as a function of the number of sites oc-
cupied by the pattern n, both Rg and S obey power law
scalings given by Rg ∼ n
ν and S ∼ nσ, respectively. For
solid patterns these exponents are ν ∼ 0.5 and σ ∼ 0.5,
corresponding to effective circular and non fractal pat-
terns. As the nutrient consumption increases, the pat-
terns tend to papillary-like shapes for which the exponent
σ increases towards the value 1 and the exponent ν varies
in the range [0.50, 0.60], indicating a fractal morphology
for the tumor.
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III. CYTOTOXIC CHEMOTHERAPEUTIC
DRUGS
The primary aim of the antitumoral treatment with
chemotherapeutic drugs is to kill or at least to stop the
proliferation of the cancer cells. In general, the drugs
should act only on proliferating cells, mainly the cancer
ones. However, drugs also destroy proliferating normal
cells promoting several collateral effects [27]. Indeed, ep-
ithelial cells from the respiratory and gastro-intestinal
systems, which frequently reproduce in order to substi-
tute their dead counterparts, are strongly affected. In
this section, we analyze a simple chemotherapeutic model
in which the complex details of the cell-cycling responses
to the drugs are taking into account by an effective ki-
netic model.
A. The model
FIG. 1: Temporal profile of drugs concentration at the capil-
lary vessel.
As used in previous works [28], the chemotherapy
is modelled by a periodic delivery of cytotoxic drugs
through the same capillary vessel supplying the nutrients
to the tissue. Several cytotoxic drugs and their properties
were exhaustively studied such as amsacrine, cisplatin,
cyclophosphamide, cytarabine, mustine, and anthracy-
cline [29]. Here, the numerous barriers involved in tumor
drug delivery [30] were not considered, and the treatment
begins when the tumor mass contains N0 cancer cells.
When a dose is applied, the drug concentration in the
capillary assumes a value Q˜0. By hypothesis, this con-
centration level decays exponentially in time, simulating
the gradual drug elimination by the organism. New doses
are periodically administered at time intervals τ . So, the
drug concentration at the capillary, Q˜(T ), is a function
of time written as
Q˜(T ) =

0, if T < T0
Q˜0 exp [−(T − lτ)/T×], if T0 + lτ ≤ T <
T0 + (l + 1)τ
,
(7)
where l = 0, 1, 2 . . . is the number of applied doses, T× is
the characteristic time for the drug elimination by the or-
ganism and T0 is the time at which the treatment begins.
The functional form of Q˜(T ) is shown in Fig. 1.
As the nutrients, drugs diffuse from the capillary ves-
sel toward the individual cells and their concentration
Q(~x, t) at any lattice site at each time step is given by
the stationary solution of the diffusion equation
∂Q
∂t
= DQ∇
2Q− Γ2Q− λQΓ
2Qσc. (8)
The first, second and third terms on the right hand side
represent drug diffusion, natural degradation and absorp-
tion by cancer cells, respectively. Again, this equation is
the simplest one describing the diffusion phenomenon.
Eq. (8) is written using the same dimensionless variables
of (1) and (2). Also, the parameters Q˜0 and DQ can
be make equal to the unity without generality loss. The
boundary conditions are the same used for the nutrient
fields, except at the capillary vessel where the concentra-
tion at each time step is given by Eq. (7).
Finally, a single change is introduced into the cell dy-
namics described in section II: an additional chance of
death occurs whenever a cancer cell enters mitosis. Thus,
every time a cancer cell divides, each one of the generated
cells can die with probability
P
(Q)
del (~x) = 1− exp
−( Q(~x)
σc(~x) θ
(Q)
del
)2 . (9)
The parameter θ
(Q)
del controls the cell sensitivity to the
drugs. Also, since in the original nutrient-limited model
the normal cells do not take part on the cell dynamics, i.
e., they do not divide or die, we disregard the chemother-
apeutic effects on normal cells.
B. Results
The main aim of this work was to investigate the ef-
fects of treatments on the various morphologies, scaling
and growth laws observed in the original model. Thus,
for each morphology, determined by the fixed parameters
reported in table I, the treatment parameters, namely, τ
(the dose period), θ
(Q)
del (drug efficiency) and N0 (tumor
size at the treatment beginning) were varied. Such pa-
rameters can be directly tested in the laboratory. The
remaining parameters (λQ, Γ and T×) associated to drug
diffusion and elimination were also fixed in all the simu-
lations.
In Fig. 2, the corresponding patterns for compact,
papillary, and ramified morphologies with and without
treatment are shown. In this figure the treatment is not
able to cease tumor development. As can be seen, the
morphological tumor patterns do not change under mild
treatment. However, the regions occupied by the tumors
are larger than those without treatment. These results
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Morphology λN λM λQ α Γ θdiv θdel T×
Compact 25 10 10 2/L 2/L 0.3 0.03 4
Papillary 200 10 10 2/L 2/L 0.3 0.03 4
Ramified 200 10 10 3/L 2/L 0.3 0.01 4
Necrotic 50 25 10 3/L 2/L 0.3 0.03 4
TABLE I: Fixed parameters used in tumor growth simulations
under chemotherapeutic treatment for each morphology type.
suggest that the direct attack to the tumor might be an
inadequate treatment strategy. Indeed, the more invasive
is the tumor, higher is the possibility of the cancer cells to
reach the capillary vessel and, consequently, metastasize
successfully. Such result is in agreement with the Israel’s
claim [31] that cancer cells trigger adaptation mecha-
nisms in stress circumstances similar to those observed
in bacterial colonies. Moreover, in our model neither ge-
netic or epigenetic changes are necessary to explain the
increase of tumor aggressiveness. It naturally emerges
from the growth rules. A tumor submitted to succes-
sive chemotherapeutic treatments which do not lead to
its complete eradication may progressively become more
resistant, aggressive and malignant.
Very similar scaling laws Rg ∼ n
ν and S ∼ nσ for
the treated tumors were observed (ν and σ values are
reported in [1]). The small differences in the exponents
values for the number of tumor peripheral sites vanishes
at the asymptotical limit of tumor size. This exponents
invariance suggests that the fractal morphology is a ro-
bust aspect of these tumors and cannot be changed by
small perturbations in the cell microenvironment. Obvi-
ously, the scaling laws for Rg and S are not defined for
the tumors that cease their growth.
We have also studied the influence of the treatment
parameters (τ , θ
(Q)
del , N0) on the tumor growth curves. In
Fig. 3 the evolution in time of the total number of cancer
cells for compact tumors is shown. Depending on dose
period τ the tumors may disappear, saturate their growth
or progress according to power laws. Actually, the time
interval between two consecutive doses is a fundamental
clinical feature determining the treatment success. The
power law regime observed when τ is large means a slow
progress, neatly contrasting with the exponential growth
present in the Gompertz law describing tumor progress
without chemotherapy. The tumor size at the beginning
of the treatment is another important factor. Indeed,
the exponents of the power laws characterizing the tumor
growth are smaller when the initial tumor size is bigger.
This scenario seems to be universal. Sometimes, as shown
Fig. 3, compact tumors which began to receive drug
doses at regular intervals of τ = 5 when it containedN0 =
104 cancer cells were eliminated slower than another one
that began to be treated with N0 = 5× 10
4 cancer cells.
However, this is not the rule. For example, simulations of
papillary tumors indicate that smaller tumors are faster
eliminated when τ = 5. Finally, since the growth law
FIG. 2: Tumor growth patterns generated by the limited-
nutrient model under chemotherapeutic treatment. The pat-
terns are drawn in a gray scale where the darker gray regions
represent higher cancer cell populations, the black points rep-
resent the sites occupied by necrotic cells, and the white re-
gions represent the normal tissue. The tissue size is 500×500,
and the initial “cancer seed” is 300 sites distant from the cap-
illary. The total number of cancer cells depends on tumor
morphology and reach up to 2 × 105 for compact patterns.
Two typical patterns, without (left) and with soft treatment
(right) are shown, for (a) compact, (b) papillary, (c) ramified
morphologies and (d) patterns with a necrotic core. The fixed
parameters used for generate these morphologies are listed in
table I. Mild treatment means that the period between two
doses is large (τ = 20) and, therefore, the tumor grows contin-
uously. The other parameters are θ
(Q)
del = 0.1 and N0 = 10
4.
exponents depend on the parameter sets used, they are
not universal. Concerning the θ
(Q)
del parameter, it just
modifies the treatment efficiency.
Fractal tumors are more resistant to treatments. In
Fig. 4, the growth curves NC×T are drawn for compact,
papillary, ramified and necrotic morphologies shown in
Fig. 2. One can see that the more fractal is the tumor
larger is the required time to eliminate it. Indeed, the
lower growth rates of fractal tumors imply in a large frac-
tion of cancer cells maintained at a quiescent state. So,
since chemotherapeutic drugs considered in this model
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FIG. 3: Growth curves for compact patterns (dashed lines).
Three dose intervals were tested (τ = 5, 10, 20) in tumors with
two distinct initial sizes: N0 = 10
4 and N0 = 5× 10
4 (inset).
The exponents of the power laws (slopes of the straight lines)
are 1.3 (0.98) for the tumors with N0 = 10
4 (N0 = 5 × 10
4)
when τ = 20, and 0.05 (-0.09) when τ = 10.
only act in the dividing cells, the treatment becomes in-
efficient when the major fraction of the cancer cells are
quiescent.
FIG. 4: Growth curves for distinct tumor morphologies. The
doses were applied at intervals τ = 5 in tumors with initial
sizes N0 = 10
4.
In addition, we have studied tumor patterns exhibit-
ing a central necrotic core. The results for cancer growth
and the correspondent power laws are similar to those
found for compact patterns. The density of cancer cells
and their average division rates through the growth pat-
terns are not significatively altered when the tumors are
submitted to mild treatments (long time intervals be-
tween consecutive drug doses). Moreover, their growth
patterns are very similar to those found in the untreated
counterparts. Finally, tumors exhibiting necrotic cores
are more easily eliminated when shorter periods of the
drug administration are considered (Fig. 4).
IV. ANTIMITOTIC CHEMOTHERAPEUTIC
DRUGS
FIG. 5: Compact patterns under treatment with antimitotic
drugs. The dose period τ was varied and θ
(Q)
div = 0.3 was
fixed. The other parameters are indicated in table I. Tumors
become more and more fractal as the dose period decreases.
At a critical period the tumors reach a frozen state in which
their size remain constant during all the treatment.
Several drugs used in cancer chemotherapies do not kill
cancer cells. Instead, they aim to stop the cell cycle in
specific checkpoints. As a consequence of that, the tu-
mors cease or slow down their growth rate. Examples of
such drugs include the antimitotic agent Curacin A that
blocks the cell cycle in the M-phase, mitomycin C, dox-
orubicin, and aclarubicin, among others [29]. In order
to analyze the effects of drugs that inhibit cell division
on tumor patterns, we introduce a very simple change in
the cell dynamics of the model described in the previous
section. Instead of an additional death probability given
by Eq. (9), the division probability is modified by includ-
ing an additional term in Eq. (3). So, the new division
probability becomes
Pdiv = 1− exp
−( N
σcθdiv
)2
+
(
Q
σcθ
(Q)
div
)2 , (10)
in which the first and second terms in the exponential
argument compete between themselves stimulating and
inhibiting the cell mitosis, respectively. The parameter
θ
(Q)
div controls the drug influence on the cell division. Ob-
viously, if the exponential argument is larger than the
unity then Pdiv ≡ 0.
The biological interpretation of the present model is
very distinct from that considered in the last section.
Now, the drugs modify the intrinsic characteristics of the
cancer cells and, consequently, the tumors must behave
differently from those treated with cytotoxic agents. In-
deed, as one can see in Fig. 5, a morphological transition
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FIG. 6: Critical values θ
(Q)∗
div as a function of the dose period τ .
The symbols represent simulational data and the straight lines
the respective exponential fittings. The open circles refer to
the simulations using the parameters for the compact patterns
listed in table I. The squares (filled circles) represent the
same simulations except that T× = 6 (θdiv = 0.1). Also, the
slopes 1/4 (circle) and 1/6 (square) are indicated. In order
to estimate θ
(Q)∗
div we realized 20 independent simulations for
each value of θ
(Q)
div and considered that the growth failure for
all these tentatives means tumor latency.
for the tumor patterns when the dose periods decrease is
observed . If the period is sufficiently short the tumor size
remains constant during the therapy. Obviously, the crit-
ical period depend on other model parameters, specially
on θ
(Q)
div . In order to see this dependence, was evaluated
the critical value of θ
(Q)∗
div for which the tumors cease their
growth with probability 1 as a function of τ . A mean
field analysis of Eq. (10) provides θ
(Q)
div ∼ exp(−τ/T×),
in agreement with the simulations as indicated in Fig. 6.
Thus, it was found an exponential decay with an univer-
sal characteristic length T× that is independent of the
other model parameters. This law, relating two impor-
tant clinical parameters, is valid for an wide set of param-
eter values. In addition to the compact tumors shown in
figure 5, it was also simulated papillary tumors under an-
timitotic treatment, and a similar morphology transition
was observed.
Fig. 7 shows that these morphological transitions oc-
curred at well defined θ
(Q)
div values. Near the critical value,
instabilities in the reaction-diffusion equations lead to
a branching growth [15]. Below this threshold the cell
death rate equals cell division, and the tumor growth ef-
fectively stops. This qualitative behavior near the tran-
sition will probably not be observed in experimental tu-
mors, since a very reliable determination of θ
(Q)
div is very
difficult. On the other hand, experiments exhibiting both
regimes, above and below the critical value, are realiz-
able today, due to the great advances in drug delivery
control. Such assays might corroborate the complex be-
haviors predicted by our model.
The antimitotic treatment affects both the growth and
FIG. 7: Morphological transitions at θ
(Q)∗
div . The patterns
were originally compact and the model parameters are listed
in table I. The dose period was fixed at τ = 2 and θ
(Q)
div varied
around its critical value.
scaling laws. The compact patterns in the original model,
for which the gyration radius and number of occupied
sites on the tumor border scale as the square root of the
total number of occupied sites (i. e. ν = σ = 1/2), be-
come progressively more fractal as the dose intervals are
decreased. Consequently, it was obtained ν > 1/2 and
σ > 1/2 indicating fractal tumors with a fractal dimen-
sion given by df = 1/ν. In general, all the tumors become
more fractal when submitted to antimitotic treatments.
So, there is a neat contrast with the invariance of the
fractal dimension of the growing tumors under the cy-
totoxic treatment described in the previous section. In
Fig. 8 the increase in the number of cancer cells relative
to the treatment beginning (NC −N0) is plotted, for dis-
tinct dose intervals, as a function of the time afterwards
the treatment beginning (T − T0). These curves suggest
power laws for the time evolution of the number of cancer
cells with a weak dependence on the τ parameter. Indeed,
we have (NC − N0) ∼ (T − T0)
β whit β ∈ [1.2, 1.4]. As
τ decreases, the number of tumor cells initially decays
for a while, but subsequently recovers its growth (inset
of Fig. 8). Below a given dose interval, NC decreases
monotonically up to a constant value.
In order to analyze the cell division rates through
the tumor, we computed the average cancer cell density
(〈σc〉) and cell division rate (wdiv) along a longitudinal
cut across the growth pattern. These average values were
plotted as a function of the distance from the capillary
vessel. In Fig. 9 these plots are shown for compact pat-
terns treated with distinct τ values. For larger τ values
(Fig. 9(a)) both, division rate and cancer cell density,
have sharp maxima on the tumor border in front and
opposite to the capillary vessel. Notice that the peaks
for division rate are significatively narrower than those
for cancer cell density, demonstrating that the prolifer-
ative fraction of the tumor comprises just a small rim
located at the tumor border. As the treatment is inten-
sified (shorter τ values are considered) the cell densities
through the tumors become more uniform, whereas the
division rates continue exhibiting sharp maxima at the
tumor borders (Figs. 9(b) and (c)). If τ is sufficiently
short in order to halt the tumor growth, the division
rates and cancer densities become uniform along the tu-
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FIG. 8: Growth curves (dashed lines) for the papillary pat-
terns under antimitotic therapy. The dose intervals used were
τ = 20, 10, 7, 6, 5, 4, 3, 2 and the upper curves represent the
larger intervals. For the larger dose intervals (τ ≥ 5) the tu-
mor growth follows power laws with exponents in the range
[1.2,1.4]. For shorter intervals (τ ≤ 4), the curves are shown
in a semi-log plot (inset). In these simulations θ
(Q)
div = 0.3 was
used in addition to the parameters of table I.
mor (Fig. 9(d)). So, in these cases the division rates are
counterbalanced by the death rates, leading to a vanish-
ing net rate of cancer growth. All these results show that
the tumor patterns are altered when the mitotic proper-
ties of the cancer cells are modified by external agents.
V. CONCLUSIONS
In the present work, a reaction-diffusion model to sim-
ulate the effects of chemotherapies on the growth of carci-
nomas “in situ” have been studied. The model includes
cell death and division, competition among cancer and
normal cells by nutrients and periodical drug adminis-
tration. Two kinds of chemotherapies, using cytotoxic
and antimitotic drugs, were modelled.
In the cytotoxic model the tumors can be completely
eradicated, cease their growth or grow continuously. The
last case occurs when the treatment is inefficient or the
intervals between consecutive doses of drugs are large.
Moreover, the morphologies and scaling laws of the grow-
ing tumor patterns are preserved. In contrast, for ther-
apeutic approaches using antimitotic agents a morpho-
logical transition in the tumor patterns was observed.
The growth patterns become progressively more fractal
as more effective treatments (shorter intervals between
consecutive doses and/or more efficient drugs) are con-
sidered.
Such morphological transitions are similar to re-
cent studies claiming that bacterial colonies exposed to
non-lethal concentrations of antibiotics exhibit drastic
changes in their growth patterns [32]. For bacteria, these
changes were imputed to variations in bacterial proper-
ties such as metabolic load and chemotaxis. In turn,
normal and cancer cells cultured in monolayer and colla-
gen gel exhibit a dynamical transition in their aggrega-
tion regimes as an adaptive response to the growth con-
straints imposed by high cell population density or long
permanence in culture [33]. Again, the results obtained
in the present work are in agreement with the point of
view that cancer cells can develop an integrated defense
program against stress situations similar to the response
of bacterial colonies facing severe and sustained threats
[31]. However, as far as we are concerned, there are no
reports on cancer literature concerning transitions mor-
phologies in the histological patterns of tumors submitted
to chemotherapy. Thus, formal models like the one pro-
posed in this paper, generally not familiar for the most
of the biomedical researchers [34], can guide and refine
new experiments intended to analyze such morphological
transitions. Currently, experiments “in vitro” with can-
cer cells are being performed in our laboratories in order
to investigated those morphological transitions.
It is important to mention that, usually, real effective
treatments employ several therapeutic methods simul-
taneously [27]. So, a more realistic chemotherapeutic
model should consider combined cytotoxic and antimi-
totic treatments. Nevertheless, in these cases relevant
features such as the robustness of the tumors fractal scal-
ing and the morphology transitions can be masked. At
last, we are modelling others cancer therapeutic strate-
gies, such as virus and immunotoxins therapies, as well as
the combination of distinct treatments by using reaction-
diffusion models like that considered in this paper.
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